Annual CFF
-$6.81 M
-$237.57 M-102.95%
31 December 2023
Summary:
Standard BioTools annual cash flow from financing activities is currently -$6.81 million, with the most recent change of -$237.57 million (-102.95%) on 31 December 2023. During the last 3 years, it has fallen by -$27.67 million (-132.65%). LAB annual CFF is now -102.95% below its all-time high of $230.76 million, reached on 31 December 2022.LAB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$2000.00
+$28.36 M+99.99%
30 September 2024
Summary:
Standard BioTools quarterly cash flow from financing activities is currently -$2000.00, with the most recent change of +$28.36 million (+99.99%) on 30 September 2024. Over the past year, it has increased by +$1.16 million (+99.83%). LAB quarterly CFF is now -100.00% below its all-time high of $212.96 million, reached on 30 June 2022.LAB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$49.10 M
+$1.16 M+2.31%
30 September 2024
Summary:
Standard BioTools TTM cash flow from financing activities is currently -$49.10 million, with the most recent change of +$1.16 million (+2.31%) on 30 September 2024. Over the past year, it has dropped by -$43.02 million (-708.08%). LAB TTM CFF is now -119.79% below its all-time high of $248.15 million, reached on 30 June 2022.LAB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LAB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -103.0% | +99.8% | -708.1% |
| 3 y3 years | -132.7% | -100.0% | -639.9% |
| 5 y5 years | -111.8% | -100.1% | -1859.8% |
LAB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -103.0% | at low | -100.0% | +100.0% | -119.8% | +2.3% |
| 5 y | 5 years | -103.0% | at low | -100.0% | +100.0% | -119.8% | +2.3% |
| alltime | all time | -103.0% | at low | -100.0% | +100.0% | -119.8% | +2.3% |
Standard BioTools Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2000.00(-100.0%) | -$49.10 M(-2.3%) |
| June 2024 | - | -$28.36 M(+43.7%) | -$50.26 M(+109.6%) |
| Mar 2024 | - | -$19.73 M(+1867.4%) | -$23.98 M(+252.2%) |
| Dec 2023 | -$6.81 M(-103.0%) | -$1.00 M(-13.8%) | -$6.81 M(+12.1%) |
| Sept 2023 | - | -$1.16 M(-44.1%) | -$6.08 M(+23.6%) |
| June 2023 | - | -$2.08 M(-18.5%) | -$4.92 M(-102.3%) |
| Mar 2023 | - | -$2.56 M(+847.4%) | $210.13 M(-8.9%) |
| Dec 2022 | $230.76 M(+1345.9%) | -$270.00 K(+5300.0%) | $230.76 M(-3.2%) |
| Sept 2022 | - | -$5000.00(-100.0%) | $238.32 M(-4.0%) |
| June 2022 | - | $212.96 M(+1078.2%) | $248.15 M(+607.8%) |
| Mar 2022 | - | $18.07 M(+147.7%) | $35.06 M(+119.7%) |
| Dec 2021 | $15.96 M(-23.5%) | $7.30 M(-25.7%) | $15.96 M(+75.5%) |
| Sept 2021 | - | $9.82 M(-7484.2%) | $9.09 M(-53.8%) |
| June 2021 | - | -$133.00 K(-87.0%) | $19.69 M(-3.2%) |
| Mar 2021 | - | -$1.03 M(-337.5%) | $20.33 M(-2.5%) |
| Dec 2020 | $20.86 M(+647.6%) | - | - |
| Dec 2020 | - | $432.00 K(-97.9%) | $20.86 M(-6.1%) |
| Sept 2020 | - | $20.42 M(+3895.5%) | $22.21 M(+1278.6%) |
| June 2020 | - | $511.00 K(-201.6%) | $1.61 M(-24.7%) |
| Mar 2020 | - | -$503.00 K(-128.2%) | $2.14 M(-23.3%) |
| Dec 2019 | $2.79 M(-95.2%) | - | - |
| Dec 2019 | - | $1.78 M(-1085.6%) | $2.79 M(-95.4%) |
| Sept 2019 | - | -$181.00 K(-117.4%) | $60.96 M(-0.1%) |
| June 2019 | - | $1.04 M(+607.5%) | $61.00 M(+5.4%) |
| Mar 2019 | - | $147.00 K(-99.8%) | $57.87 M(+0.4%) |
| Dec 2018 | $57.66 M(+98.8%) | $59.95 M(<-9900.0%) | $57.66 M(-2831.4%) |
| Sept 2018 | - | -$140.00 K(-93.3%) | -$2.11 M(-107.9%) |
| June 2018 | - | -$2.09 M(+3510.3%) | $26.89 M(-7.1%) |
| Mar 2018 | - | -$58.00 K(-132.0%) | $28.94 M(-0.2%) |
| Dec 2017 | $29.00 M | $181.00 K(-99.4%) | $29.00 M(+0.7%) |
| Sept 2017 | - | $28.86 M(<-9900.0%) | $28.80 M(<-9900.0%) |
| June 2017 | - | -$49.00 K(-1733.3%) | -$64.00 K(-156.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | $3000.00(-127.3%) | $114.00 K(-1.7%) |
| Dec 2016 | $116.00 K(-97.8%) | -$11.00 K(+57.1%) | $116.00 K(-40.5%) |
| Sept 2016 | - | -$7000.00(-105.4%) | $195.00 K(-43.6%) |
| June 2016 | - | $129.00 K(+2480.0%) | $346.00 K(-78.5%) |
| Mar 2016 | - | $5000.00(-92.6%) | $1.61 M(-69.8%) |
| Dec 2015 | $5.34 M(-97.3%) | $68.00 K(-52.8%) | $5.34 M(-15.3%) |
| Sept 2015 | - | $144.00 K(-89.7%) | $6.30 M(-7.1%) |
| June 2015 | - | $1.40 M(-62.6%) | $6.79 M(+3.4%) |
| Mar 2015 | - | $3.73 M(+262.3%) | $6.56 M(-96.7%) |
| Dec 2014 | $200.33 M(+3350.3%) | $1.03 M(+64.3%) | $200.33 M(-0.6%) |
| Sept 2014 | - | $627.00 K(-46.4%) | $201.60 M(-0.2%) |
| June 2014 | - | $1.17 M(-99.4%) | $202.06 M(+0.3%) |
| Mar 2014 | - | $197.50 M(+8468.3%) | $201.54 M(+3371.2%) |
| Dec 2013 | $5.81 M(-88.0%) | $2.31 M(+113.2%) | $5.81 M(+180.6%) |
| Sept 2013 | - | $1.08 M(+65.5%) | $2.07 M(-96.2%) |
| June 2013 | - | $653.00 K(-63.0%) | $55.11 M(+3.4%) |
| Mar 2013 | - | $1.77 M(-223.4%) | $53.33 M(+9.9%) |
| Dec 2012 | $48.52 M(-31.0%) | -$1.43 M(-102.6%) | $48.52 M(-0.8%) |
| Sept 2012 | - | $54.13 M(-4872.9%) | $48.89 M(-909.8%) |
| June 2012 | - | -$1.13 M(-62.7%) | -$6.04 M(-1.2%) |
| Mar 2012 | - | -$3.04 M(+185.3%) | -$6.11 M(-108.7%) |
| Dec 2011 | $70.37 M(+1753.2%) | -$1.06 M(+33.1%) | $70.37 M(-5.6%) |
| Sept 2011 | - | -$800.00 K(-33.8%) | $74.56 M(-1.9%) |
| June 2011 | - | -$1.21 M(-101.6%) | $76.02 M(-2.2%) |
| Mar 2011 | - | $73.44 M(+2244.1%) | $77.69 M(+1946.1%) |
| Dec 2010 | $3.80 M(-77.6%) | $3.13 M(+379.8%) | $3.80 M(+471.8%) |
| Sept 2010 | - | $653.00 K(+40.1%) | $664.00 K(+5936.4%) |
| June 2010 | - | $466.00 K(-202.4%) | $11.00 K(-102.4%) |
| Mar 2010 | - | -$455.00 K | -$455.00 K |
| Dec 2009 | $16.94 M(+167.8%) | - | - |
| Dec 2008 | $6.33 M(-83.2%) | - | - |
| Dec 2007 | $37.55 M(+20.7%) | - | - |
| Dec 2006 | $31.12 M | - | - |
FAQ
- What is Standard BioTools annual cash flow from financing activities?
- What is the all time high annual CFF for Standard BioTools?
- What is Standard BioTools annual CFF year-on-year change?
- What is Standard BioTools quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Standard BioTools?
- What is Standard BioTools quarterly CFF year-on-year change?
- What is Standard BioTools TTM cash flow from financing activities?
- What is the all time high TTM CFF for Standard BioTools?
- What is Standard BioTools TTM CFF year-on-year change?
What is Standard BioTools annual cash flow from financing activities?
The current annual CFF of LAB is -$6.81 M
What is the all time high annual CFF for Standard BioTools?
Standard BioTools all-time high annual cash flow from financing activities is $230.76 M
What is Standard BioTools annual CFF year-on-year change?
Over the past year, LAB annual cash flow from financing activities has changed by -$237.57 M (-102.95%)
What is Standard BioTools quarterly cash flow from financing activities?
The current quarterly CFF of LAB is -$2000.00
What is the all time high quarterly CFF for Standard BioTools?
Standard BioTools all-time high quarterly cash flow from financing activities is $212.96 M
What is Standard BioTools quarterly CFF year-on-year change?
Over the past year, LAB quarterly cash flow from financing activities has changed by +$1.16 M (+99.83%)
What is Standard BioTools TTM cash flow from financing activities?
The current TTM CFF of LAB is -$49.10 M
What is the all time high TTM CFF for Standard BioTools?
Standard BioTools all-time high TTM cash flow from financing activities is $248.15 M
What is Standard BioTools TTM CFF year-on-year change?
Over the past year, LAB TTM cash flow from financing activities has changed by -$43.02 M (-708.08%)